B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosidase Enzymes in the Plasma of Patients With a Localized Cancer.
NCT ID: NCT07236177
Last Updated: 2025-11-19
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
EARLY_PHASE1
220 participants
INTERVENTIONAL
2025-12-01
2027-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Patients' blood plasma will be analyzed with a mixture of volatile organic compound-based probes, each targeting a specific glycosidase. The presence of a given glycosidase in a blood sample would thus be revealed by the detection of an ethanol isotope in the gas phase.
3 groups of patients with localized cancer (breast, prostate, pancreas) will be enrolled, as well as 1 group of patient without any cancer (control group).
For the patients, two 5ml plasma samples will be collected, one before and one after surgery for localized cancers. For healthy volunteers, only one 5ml plasma sample will be collected.
The primary objective will be to compare the levels of glycosidases measured in the blood of patients followed for localized cancer and referred for first surgery compared to control patients without cancer.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Testing Spectrosense EVA System for Detection of Pancreatic Cancer by Analyzing Volatile Organic Compounds (VOCs) in Exhaled Air
NCT01994681
A Prospective Study of Liquid Biopsy for Pancreatic Cancer Early Detection
NCT06166147
A Case-control Study Comparing Glycaemic Control in Pancreatic Cancer Patients vs Healthy Matched Individuals.
NCT05583890
Diagnostic Accuracy of Circulating Tumor Cells (CTCs) and Onco-exosome Quantification in the Diagnosis of Pancreatic Cancer - PANC-CTC
NCT03032913
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma (VAPOR2)
NCT07243262
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
breast cancer
blood plasma sample
For each patient, 5ml blood sample will be needed before the surgery and another 5ml blood sample one month after the surgery.
pancreatic cancer
blood plasma sample
For each patient, 5ml blood sample will be needed before the surgery and another 5ml blood sample one month after the surgery.
pulmonary cancer
blood plasma sample
For each patient, 5ml blood sample will be needed before the surgery and another 5ml blood sample one month after the surgery.
no cancer
no history of cancer
blood sampling
5ml blood sample for control arm
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
blood plasma sample
For each patient, 5ml blood sample will be needed before the surgery and another 5ml blood sample one month after the surgery.
blood sampling
5ml blood sample for control arm
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Group 2: 40 patients with definitively diagnosed, untreated, localized solid lung cancer referred for initial surgical treatment.
Group 3: 40 patients with definitively diagnosed, untreated, localized solid pancreatic cancer referred for initial surgical treatment.
Group 4: 100 control patients with no cancer diagnosis or history of solid or hematological cancer.
Exclusion Criteria
* Patients benefiting from enhanced protection, namely: minors, pregnant/breastfeeding women, persons deprived of their liberty by a judicial or administrative decision, persons staying in a social care facility, adults under legal protection
Specific criteria for groups 1, 2, and 3:
* Cancer patients undergoing oncological treatment.
* Cancer not proven by anatomopathological examination.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Poitiers University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025-A01440-49
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.